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Introduction
HIV-1 can persist in a latent form in resting memory
CD4+ cells and macrophages carrying an integrated
copy of the HIV genome. Because of the presence of
these stable reservoir cells, eradication by antiretroviral
therapy is unlikely and in order to achieve eradication,
alternative treatment options are required.
Materials and methods
Recently, we have described a successful hematopoietic
stem cell transplantation in an HIV-1 infected patient
transferring donor derived cells with a natural resistance
against HIV infection. These haematopoietic stem cells
engrafted, proliferated and differentiated into mature
myeloid and lymphoid cells.
Results
At present the patient is more than five years after allo-
geneic transplantation without requirement of any antire-
troviral treatment. Analyzing peripheral blood cells and
different tissue samples including gut, liver, and brain, no
viral load or proviral DNA could be detected.
Conclusions
There is a degree of optimism that gene therapy in com-
bination with SCT can improve HIV-1 treatment. After
nearly 30 years of research and progress HIV infection
has become a chronic disease in developed countries.
However, the evolution of this infectious agent, due to its
rapid mutation, is quite unpredictable. Therefore, strate-
gies to eliminate the virus from the body to achieve cure
are desirable. Currently, HIV-targeted gene therapy
appears to have great potential as an effective strategy
that may eliminate or reduce the need for antiretroviral
therapy and achieve elimination of the viral reservoir.
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